Using preclinical models to discover new treatments for advanced prostate cancer

Despite many new treatments for advanced (castration-resistant) prostate cancer, this aggressive from of cancer remains incurable. A team of researchers at Monash University, Melbourne have established new preclinical models of advanced prostate cancer that can be studied in the laboratory.

Patient-derived xenografts (PDX) are primary tumours collected from a patient, which are then grown up in the laboratory setting. These tumours can be closely studied and new treatments can be tested prior to taking a drug to clinical trial.

The study, published in European Urology, successfully established a bank of castration-resistant prostate cancer PDX models and then used these models to test a range of drugs to see if they could slow growth of the cancer.

A particular set of drugs that inhibit protein synthesis in the cell were found to reduce tumour growth when used in combination. These exciting findings provide a strong rationale for testing these drugs in patients as part of a clinical trial.

Read more in our journal article reviews.

This entry was posted in Knowledge exchange, Men's health, Middle-aged and older males, Prostate cancer. Bookmark the permalink.
Website by Essendon Creative